Efficacy and Tolerability for Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell lung Cancer by Abdou, Ehab et al.
 International Journal of Sciences: 
Basic and Applied Research 
(IJSBAR) 
 
ISSN 2307-4531 
(Print & Online) 
 
http://gssrr.org/index.php?journal=JournalOfBasicAndApplied 
--------------------------------------------------------------------------------------------------------------------------- 
Efficacy and Tolerability for Neoadjuvant Chemotherapy 
in Locally Advanced Non-Small Cell lung Cancer 
Ehab Abdou a*, Khaled Al-Shahhat b, Mohamed Gaafar c 
aDepartment Of Radiation Oncology, AL-Azhar University, Cairo, Egypt. Consultant Oncology Bahrain 
oncology center SMC, Bahrain 
b Department Of Radiation Oncology, AL-Azhar University, Cairo, Egypt 
cDepartment Of Epidemiology, Shebeen Alkoom University, Almunofyia, Egypt 
aEmail: dr_ehab_abdo@yahoo.com 
bEmail: khshahhat@yahoo.com 
cEmail: mwesam@hotmail.com 
 
 
 
Abstract 
The objective of this study is to assess Efficacy and tolerability for neoadjuvant chemotherapy in Locally 
advanced non-small Cell lung cancer. This research is a retrospective study. Between May 2011 and April 2013, 
20 patients with stage III A,B Non-small cell lung cancer (NSCLC) referred to Oncology department, Salmanyia 
Medical Complex (SMC) were treated with combined induction chemotherapy consisting of 3 cycles of 
cisplatin (80 mg/m2) day I, and Gemcitabine 1250 mg/m2 by intravenous infusion day 1 and 8. Cycles were 
repeated every 3 weeks. The chemotherapy was followed with thoracic irradiation starting 4-6 weeks after 
induction chemotherapy up to 60 Gy/6weeks. Patients were assessed for the response and tolerability. 
The overall response rate was 40% with no complete response obtained. At a median follow up of 18 months, 
the overall survival was 75% and median survival was 12 month.  
------------------------------------------------------------------------ 
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Treatment toxicity was mainly hamotological in 75% of patients. No grades III or IV toxicity were registered. 
Nausea and vomiting Grade III was reported in 15 patients (75%), esophagitis grade I in 3 patients (15%), 
radiation pneumonitis grade I, II in 5 patients (25%), alopecia in 6 patients (30%), nephrotoxicity in 3 patients 
(15%). As a conclusion we can say that the combination chemotherapy of cisplatin and gemcitabine is a 
tolerable and active induction chemotherapy regimen for patients with locally advanced NSCLC. Sequential 
radiotherapy given after induction chemotherapy is tolerable with potential improvement in both locoregional 
control and survival. 
Keywords:  neoadjuvant ; non-small cell lung cancer; chemotherapy. 
1. Introduction 
Cancer is the leading cause of death in many countries and Bronchogenic carcinoma is a major cause of death 
from cancer [1]. It is generally accepted that surgical resection can be effective in stage I, II and in some cases 
of stage III patients with non-small cell lung cancer (NSCLC). Unfortunately, more than 75% of NSCLC 
patients are inoperable because of either distant metastatic disease or disease confined to one hemithorax with 
one or more criteria of unresectability at the time of presentation. The prognosis of such inoperable patients is 
poor. The high proportion of disseminated disease in such inoperable patients has justified the numerous 
attempts to improve systemic treatment for several years [1,2]. 
There were also many previous studies that showed prolongation of median survival of locally advanced or 
metastatic NSCLC by cisplatin-based chemotherapy, when compared with best supportive care [2]. 
Gemcitabine (GEM) is a nucleoside analog with confirmed activity against several solid tumors, especially 
NSCLC [1,3]. It is well tolerated when given in doses of 1,000 to 1,250 mg/m2 weekly for 3 weeks followed 
by a 1-week rest. Single drug response rates of 17% to 28% have been reported for NSCLC [1,2, 7]. Several 
trials have demonstrated significant benefit to induction chemotherapy in reducing the distant failure rate, 
however, poor local control remains a major issue in the locally advanced disease [5]. 
This retrospective study was conducted to evaluate neoadjuvant chemotherapy (Gemcitabine plus cisplatin) in 
treatment of locally advanced NSCLC patients followed by radiotherapy. 
Response rate and toxicity profile were assessed as well as quality of life (QOL) and time to disease 
progression.  
2. Patients and methods 
Patient selection and pretreatment evaluation: 
Between May 2011 and April 2013, 20 patients with stage III A,B Non-small cell lung cancer (NSCLC). were 
entered into the study. 
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2.1 Eligible patients should have 
• histological or cytological diagnosis of NSCLC,  
• stage III (A-B) according to TNM staging [6]. 
• 18 and up to 65 years of age. 
• Eastern cooperative oncology group (ECOG) performance status of 0-2[7],   
• life expectancy of more than 12 weeks. 
• normal renal, liver, and hematological profile.  
• no prior radiation therapy or chemotherapy.  
Pretreatment evaluation included patient history, clinical examination, laboratory investigations (blood count, 
liver function tests, renal function tests) radiological studies (chest x-ray, computerized tomography of the chest, 
pelvi-abdominal ultrasound)  Bone scan and CT of the brain when indicated.  
2.2 Treatment methods 
Eligible patients were stratified according to sex, performance status, disease stage and histopathological types 
and were treated as follow: 
Twenty patients were treated with induction chemo-therapy in the form of 3 cycles of the following 
combination: cisplatin (80 mg/m2) given by intravenous infusion over 30-60 minutes day 1, and Gemcitabine 
1250 mg/m2 intravenously infused over 30 minutes day 1, 8. Cycles were repeated every 3 weeks. Before and 
after administration of cisplatin, patients were hydrated with 2 liters of 5% dextrose and 0.9% saline, and 250m1 
of manitol 10%. A combination of intravenous dexamethasone and ondansetrone were given before 
chemotherapy to control vomiting . 
2.3 Radiation Therapy Planning 
Thoracic irradiation was started 4-6 weeks after induction chemo-therapy using 18 MV LINAC machine. 
2.3.1 Position 
All patients were treated in supine position. 
2.3.2 Localization 
 CT-based treatment planning was done in the same position as simulation.  
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2.3.3 Fields arrangements 
 We used of complex; multiple field arrangement utilizing wedges filters, tissue compensators, field weighting, 
and bolus to achieve an adequate coverage of the target volume. 
2.3.4 Gross target volume (GTV) 
 Accurate delineation of gross tumor volume of lung cancer depends on positive findings obtained from all 
diagnostic modalities used in pretreatment evaluation, including computed tomography whichever was positive 
or magnetic resonance imaging (MRI) scans.  
2.3.5 Planned target volume (PTV) 
 The treatment volume encompasses the primary tumor with a 2cm safety margin around and the entire width of 
the mediastinum including ipsilateral and contralateral hilum, and extends from sternal notch to at least 5-6 cm 
below the level of the carina in upper or middle lobes, or hilar tumors, and to the levels of the diaphragm in 
lower lobe lesions. In undifferentiated tumors or upper lobe lesions, the supraclavicular regions were also 
included in the treatment volume. 
2.3.6 Dose 
 Patients were treated with 18 MV LINAC machine. A tumor dose of 60 Gy/6 weeks, 5 fractions/week was 
delivered with exclusion of the spinal cord after 40 Gy. 
2.3.7 Dosemetric evaluation 
 The 3-D computer planning system was used to have the best dose homogenicity to cover the target volume 
into the 95 % isodose curve. Doses to the spinal cord, heart, lungs, liver, and kidneys were kept within the 
tolerance limits to reduce sequelae and morbidity. Weekly verification of the target volume was done. Patients 
were assessed on daily bases for proper repositioning and tolerance to radiation therapy. Also weekly CBC was 
done for any hematological toxicity detection. 
2.4 Post-treatment evaluation 
All patients had regular weekly follow up visits during treatment and monthly after treatment, in each visit 
complete physical examination was performed. Laboratory investigations (CBC, liver functions, kidney 
functions) were done before each chemotherapy cycle and every two weeks during radiotherapy and 
radiological investigations (chest X-ray and pelvi-abdominal sonar) was done every 2 months, CT chest was 
done 2 months after end of treatment and then every 4 months, other investigations were done (e.g bone scan) 
when indicated.  
Patients were assessed for local control, distant metastasis, time to recurrence, quality of life and treatment 
toxicity. 
4 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2016) Volume 25, No  2, pp 1-14 
The final evaluation for response was performed 2-3 months after end of treatment. Response and toxicity were 
evaluated according to WHO criteria[8] as follows 
- Complete response (CR): was defined as complete disappearance of all measurable lesions for a minimum 
of 4 weeks. 
- Partial response (PR): was defined as a 50% or more decrease in the sum of the products of perpendicular 
diameters of all measurable lesions for a minimum of 4 weeks. 
- Stable disease (SD): was defined as a less than 25% decrease in the sum of products of measurable lesions 
or a less than 25% increase. 
- Progressive disease (PD): was defined as a 25% or more increase in the size of measurable lesions or the 
appearance of new lesions. 
All toxic reactions are graded 0-5 implying: none (0), mild (1), moderate (2), sever (3), life threatening (4); and 
fatal (5) [9]. 
2.5 Statistical Analysis 
Statistical package for social sciences (SPSS) version 16 was used for data base construction and analysis. 
Quantitative variables were summarized using mean and SD, median minimum and maximum values. 
Qualitative data were summarized using frequencies and percentage. The starting point was the date of 
diagnosis for survival and response while it was the end of treatment for the time to relapse. Immediate local 
failure was counted whenever residual tumor is detected. 
Survival analysis was done using Kaplan- Meier, comparisons between survival curves was done using Log-
rank test. Differences were considered significant when p was <0.05 and highly significant when p<0.01. (16). 
3 . Results 
3.1 Patient characteristics 
Table 1 shows pretreatment characteristics in both groups. A total of 20 patients were included in the study. 
Thirteen patients  (65%) were under 40 year old while 7 (35%) were over 40 year old. The mean age was 
44.2 6.3 (Range 25               
only 2 patients. 
Eleven patients (55%) had ECOG performance status 0-1, and 9 patients (45%) had ECOG performance status 
2. Squamous cell carcinoma was reported in nine (45%) patients, adenocarcinoma in seven patients (35%) and 
large cell carcinoma in four (20%) patients. 
 
5 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2016) Volume 25, No  2, pp 1-14 
Table 1: Patient characteristics in both study groups. 
Characteristics No % 
Age (years) 
≤ 40 13 65 
 >40 7 35 
Range 25-65 
Mean±SD 45.3±6.7 
Sex 
Male 18 90 
Female 2 10 
Performance Status 
     0-1 11 55 
     2 9 45 
Histopathological types 
Squamous cell 9 45 
Adenocarcinoma 7 35 
Large cell carcinoma 4 20 
Tumor stage 
IIIA 11 55 
IIIB 9 45 
Tumor grade 
Moderate  differentiated tumors 13 65 
Poorly differentiated tumors 7 35 
 
Moderately differentiated tumors were reported in 13 (65%) of patients, while 7 (35%) had poorly differentiated 
tumors in both groups. stage IIIA was documented in eleven patients (55%) while 9 patients (45%) had stage 
IIIB.  
3.2 Response 
None of our patients achieved a complete response (CR). There were 13 patients with partial response (65%). 
Two patients (10%) had progressive disease and 5 patients (25%) had stable disease. See (table 2).  
Response rate analysis based on prognostic factors. 
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Table 2: Response rate 
Response rate No % 
Partial Response (PR) 13 65 
Stable disease (SD) 5 25 
Progressive disease (PD) 2 10 
NB: none of our patients had complete response 
Table 3: Response rate analysis based on prognostic factors 
Prognostic factor RESPONSE P V 
PR (N 13) SD (N 5) PD (N 2)  
 No % No % No % No %  
Age (years) 0.68 
≤ 40 13 65 8 61.5 3 23 2 15.5  
     >40 7 35 5 71.4 2 28.5 0 0  
Sex 0.35 
M 18 90 12 66.66 4 22.22 2 11.11  
 2 10 1 50 1 50 0 0  
Performance Status 0.07 
     0-1 11 55 7 63.67 3 27.23 1 9  
     2 9 45 6 66.66 2 22.22 1 11.11  
Tumor stage 0.07 
IIIA 11 55 8 72.72 3 27.27 0 0  
IIIB 9 45 5 55.55 2 22.22 2 22.22  
Tumor grade 0.08 
MDT 13 65 9 69.23 3 23.07 1 7.69  
PDT 7 35 4 57.14 2 28.57 1 14.28  
PV: P Value, M: Male, F: Female MDT: Moderate  differentiated tumors  PDT: Poorly differentiated tumors 
Partial Response (PR), Stable disease (SD) and Progressive disease (PD) 
NB: none of our patients had complete response 
It was observed that younger patients with better performance status had a better response to treatment in 
comparison to the older patients and performance status less than one. The difference was not significant 
statistically. Table (3) is showing the response rate analysis based on prognostic factors. 
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3.3 Time to disease progression 
The median time to progression was 8 months. The probability of the tumor response lasting at least 6 months, 
was estimated to be 81%. Time to disease progression free survival curve is shown in (Figure 1). 
 
Figure 1: progression free survival curve 
3.4 Survival time 
Overall survival time curves are shown in Figure (2). The overall survival rate was 65% at 15 months and the 
median survival time was 16 months.  
3.5 Change of performance status after treatment 
Eight patients (40%) shifted to better scale but 3 patients (15%) showed worsening of their performance status 
dropping to performance status (PS) 3. Two patients had PS 2 and three patients had PS 1. None of our patients 
deteriorated to a PS 4.  
3.6 Treatment toxicity 
None of patients were graded as grade IV or V  all-through the course of treatment. 
3.6.1 Hematological toxicity 
The hematological toxicities were mild . Leucopenia grade I&II were represented in 2 (10%) and 3 (15%) 
patients respectively. Anemia was reported in 7 patients as grade I or II while thrombocytopenia was reported in 
4 patients (20%) at same grades (G1 and GII). 
3.6.2 Gastrointestinal toxicity 
All patients had experienced different grades of Nausea and vomiting. One patient (5%)had grade I Nausea and 
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vomiting while 15 patients (75%) had grade II. 
Grade I esophagitis was observed in two patients (10%) while one patient (5%) had Grade II . 
 
 
Figure 2: The overall survival 
Table 3: shows patient’s performance status before and after treatment 
Before After 
Scale  0 1 2 3 
No of pts     
0 4 4 0 0 0 
1 8 4 2 1 1 
2 8 4 1 1 2 
Total 12 3 2 3 
 
3.6.4 Skin toxicities 
Skin reactions were reported in two patients only as one for each grade I and II. This was the same situation for 
Radiation pneumonitis. 
3.6.5 Alopecia 
Alopecia reported in 6 (30%) patients. Stomatitis observed in 3 (15%) patients as grade I and in one (5%) 
patient as grade II. Nephrotoxicity was reported only in one (5%) patient as grade I and II. Table (4) si showing 
the toxicity profile for all patients. 
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Table 3: Change of performance status of patients in both study groups before and after treatment. 
Toxicity Grade No % 
Haematological toxicity 
Leucopenia Grade I 2 10 
Grade II 3 15 
Anaemia Grade I 3 15 
Grade II 4 20 
Thrombocytopenia Grade I 3 15 
Grade II 1 5 
Gastrointestinal toxicity 
Nausea and vomiting Grade I 1 5 
Grade II 15 75 
Grade III 3 15 
Grade IV 1 5 
Oesophogitis Grade I 2 10 
 Grade II 1 5 
Skin Reactions Grade I 1 5 
Grade II 1 5 
Alopecia  6 30 
Stomatitis  Grade I 3 15 
 Grade II 1 5 
Nephrotoxicity Grade I 1 5 
Grade II 1 5 
Radiation pneumonitis Grade I 1 5 
Grade II 1 5 
Table (4): toxicity profile for all patients according WHO grading 
4. Discussion 
Approximately 30% of NSCLC patients present with locally advanced inoperable disease [11]. 
Long-term results for these patients after radiotherapy alone are dismal with only 15% surviving beyond 2 years 
[11,12]. Both poor local control and a high rate of early distant dissemination contribute to the poor outcome. 
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At present there is a strong rationale for combining chemotherapy and radiotherapy as the primary treatment of 
locally advanced NSCLC. In addition to early effective systemic chemo-therapy, concurrent radiotherapy should 
result in enhanced local control where additive or synergistic effects with chemotherapy can be expected. The 
mechanisms of interaction between drugs and radiation have been extensively studied during the past years[17]. 
They include radiosenstization of hypoxic cells, inhibition of tumor cell repopulation and cellular repair 
processes, and improved drug penetration [17]. 
Obviously low rate of complete response and persistence of macroscopic residual tumor after induction 
chemotherapy are the rule in these patients and late radiation therapy may be unable to ultimately eradicate such 
resistant residium. Concurrent administration of chemotherapy and radiotherapy may be a way to overcome this 
problem. 
Hopefully, these interactions should lead to significant activity against the radioresistant and/or chemoresistant 
population in the bulk of the primary tumor, and to an improved therapeutic gain if toxicity remain acceptable. 
Cisplatin is not only one of the most effective drugs for metastatic or locally advanced NSCLC, but exihibits 
radiosensitizing proper-ties. Similarly, gemcitabine was recognized as an effective radiosensitizing agent. So 
combining cisplatin and Gemictabine and concurrent radiotherapy is highly effective in locally advanced 
NSCLC [18]. 
At the present time, eradication of micrometastases can only be achieved through the use of early effective 
systemic therapy, and clearly, definitive eradication of the primary tumor is a pre-requisite for long-term disease 
control[13]. 
Induction combination chemo-therapy regimen mostly used for locally advanced NSCLC has been the two-drug 
combination of cisplatin and Gemcitabine. The overall response rates were 26% - 67% with no or few complete 
responses[13,14,]. 
In the present study, patients received induction chemotherapy followed by radiotherapy. The partial response 
rate was 65% and the stable disease rate was 25 %. 
In a trial by Crino et al., (1999)[14], 42 patients with stage III unresectable NSCLC received 4 cycles of 
induction chemotherapy with gemicitabine (1000 mg/m2 day 1-8-15); cisplatin (100 mg/m2 day 2) every 28 
days followed by radiotherapy (54-66 Gy). The response rate was 62% with 4.7% complete remissions. 
In a retrospective study [13], 60 patients with advanced stage III NSCLC treated with 4 courses of gemcitabine 
(1000-1250 mg/m2 day 1,8) and cisplatin (70-100 mg/m2 day 2), every 28 days.  After chemotherapy 
all patients received thoracic irradiation (at a median dose of 56 Gy). The response rate was 67% with 1.6% 
complete response and 65% partial response and stable disease  was 20%. 
Bretti & his collogues [15], treated 45 patients with locally advanced NSCLC with induction chemotherapy, 
cisplatin (80 mg/m2 day 1) and Gemictabine (1000 mg/m2 day 1 and 8), to be repeated every three weeks for 
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two or three cycles followed by thoracic irradiation (56-62 Gy). The response rate was 23% and increased to 
45% when the chemotherapy courses were completed to six courses. 
In the present study, the median time to disease progression for patients was 8 months. Overall survival rate was 
65% at 15 months and median survival was 16 months. In a trial comparing induction chemotherapy followed 
by radiotherapy to radiotherapy alone, a small but statistically significant gain in survival at 2 years, in the range 
of 12-38%, was demonstrated[19]. 
On the other hand, some studies have failed to show a benefit from chemotherapy added to radiotherapy, but 
most of these negative studies used non-platinum-containing regimens or older less active chemotherapy 
combinations[20].  
In the present study there had been slightly increased toxicity rates in the combined treatment group than in the 
radiotherapy only group. 
Haematological toxicity were mild. None of patients were graded as III, IV all through the course of treatment. 
As regards to non haematological morbidity, nausea and vomiting were the most common and occurred in 100% 
of patients. Nephrotoxicity, alopecia and stomatitis were observed. Other side effects including esophagitis, skin 
reaction, radiation pneumonitis, were mild.  
In trial of induction chemo-radiotherapy [14], grade 1-2 dysphagia occurred in 5% of patients, pneumonitis in 
2.3% of patients. Hematological toxicity was the main side effect with 29% and 24% grade III, IV 
thrombocytopenia and leukopenia. 
While in another trial [13], treatment toxicity included leucopenia, grade III, IV in 20% of patients, 
thrombocytopenia grade III, IV in 30% of patients, esophagitis grade II in 9% and pneumonitis grade II in 3% 
and alopecia in 10%. 
5. Conclusion 
For patients with locally advanced NSCLC; combination chemotherapy with cisplatin and Gemcitabine is a 
tolerable and active induction chemotherapy regimen. Sequential radiotherapy given after induction 
chemotherapy is tolerable and may offers the hope of improved locoregional control and survival over 
radiotherapy alone. 
6. Recommendations 
From our study we recommending neoadjuvant combination chemotherapy followed by radiotherapy to be 
considered as an effective tolerable treatment strategy for patients with locally advanced non-small cell lung 
cancer. 
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